514 related articles for article (PubMed ID: 14755376)
1. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Rick ME; Austin H; Leitman SF; Krizek DM; Aronson DL
Am J Hematol; 2004 Feb; 75(2):96-100. PubMed ID: 14755376
[TBL] [Abstract][Full Text] [Related]
2. [A woman suffering from systemic lupus erythematosus and acquired thrombotic thrombocytopenic purpura].
Verheijen FM; Reedijk L; Fijnheer R
Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1977-81. PubMed ID: 15524134
[TBL] [Abstract][Full Text] [Related]
3. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
5. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Furlan M
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
7. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
9. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
10. [Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura].
Hulstein JJ; Rison CN; Kappers-Klunne MC; Hene RJ; Franx A; de Groot PG; Brand A; Fijnheer R
Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1972-6. PubMed ID: 15524133
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
12. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Solenthaler M; Lämmle B
Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine].
Yagi H
Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532
[TBL] [Abstract][Full Text] [Related]
14. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.
Kostousov V; Fehr J; Bombeli T
Thromb Res; 2006; 118(6):723-31. PubMed ID: 16430944
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Moake JL
Semin Hematol; 2004 Jan; 41(1):4-14. PubMed ID: 14727254
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura.
Rock G; Clark WF; Anderson D; Benny B; Sutton D; Leblond P; Sternbach M; Sontrop J;
Thromb Res; 2013 Apr; 131(4):308-12. PubMed ID: 23411128
[TBL] [Abstract][Full Text] [Related]
17. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
Tsai HM
J Am Soc Nephrol; 2003 Apr; 14(4):1072-81. PubMed ID: 12660343
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).
Böhm M; Vigh T; Scharrer I
Ann Hematol; 2002 Aug; 81(8):430-5. PubMed ID: 12223999
[TBL] [Abstract][Full Text] [Related]
19. [The role of von Willebrand protease in aetiopathogenesis of thrombotic thrombocytopenic purpura].
Suvajdzić-Vuković N
Srp Arh Celok Lek; 2007; 135(5-6):360-6. PubMed ID: 17633329
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Mannucci PM; Vanoli M; Forza I; Canciani MT; Scorza R
Haematologica; 2003 Aug; 88(8):914-8. PubMed ID: 12935979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
